ScholarIQanswers from OpenAlex & ORCID
Juan P. Frías
ResearcherPublications, citations & collaboration network
Juan P. Frías is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Juan P. Frías have?
ScholarIQindexed works
Juan P. Frías has 312 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Juan P. Frías have?
ScholarIQcitation count
Juan P. Frías has 22,446 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Juan P. Frías?
ScholarIQh-index
Juan P. Frías has an h-index of 62 in OpenAlex.
What is the i10-index of Juan P. Frías?
ScholarIQi10-index
Juan P. Frías has an i10-index of 128 in OpenAlex.
What is the ORCID of Juan P. Frías?
ScholarIQorcid
The ORCID for Juan P. Frías is on the source record.
What is the OpenAlex record for Juan P. Frías?
ScholarIQopenalex
The OpenAlex for Juan P. Frías is on the source record.
What are the most-cited papers on Juan P. Frías?
ScholarIQmost cited works
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman, Bing Liu, Xuewei Cui, Katelyn Brown
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden, Timothy S. Bailey, Liana K. Billings, Melanie J. Davies, Juan P. Frías, Anna Koroleva, Ildiko Lingvay, Patrick M. O’Neil, Domenica Rubino, Dorthe Skovgaard, Signe Olrik Rytter Wallenstein, W. Timothy Garvey, STEP 3 Investigators
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Miličević, Mark L. Hartman
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, Silvio Buscemi, Louise Christensen, Juan P. Frías, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, Sean Wharton, the STEP 5 Study Group
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E. Gimeno, Zvonko Miličević, Deborah A. Robins, Axel Haupt